As Allogene moves to follow Autolus onto the public markets, its IPO document could give hope that Cellectis’s allogeneic assets will at long last make meaningful…
Galapagos needs to impress with its cystic fibrosis triplet to have a hope of catching Vertex, while Abbott needs the Coapt study of MitraClip to reach a different…
A genome editing tie-up between Gilead and Precision Biosciences, and promising early data with Arrowhead’s RNA interference project, are two novel approaches in hep B.
Apple has obtained its first FDA clearance, putting the Apple Watch on the same footing as Alivecor’s KardiaBand – but the smaller group is fighting back.
Having won the most acquisitive crown in 2016, Stryker seems to be seeking the prize this year too, buying Invuity and spinal company K2M.
After buying Avexis for $8.7bn to access a potentially transformative treatment for spinal muscular atrophy, data approaches from Novartis.
In the Rewind trial, whose readout is due by year-end, Trulicity needs to avert heart complications and show clean safety to keep up with other glucose-lowering drugs.
It’s time for Viking, a Nash player that has climbed in tandem with one of its biotech peers, to prove itself.
Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.
As the tiny Norwegian biotech gears up to put its first asset into the clinic, investors could use an ongoing trial to handicap its chances of success.
The Danish company’s latest deal covers glucose-sensitive insulin, which could avoid hypoglycaemia in type 2 diabetes patients.